|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,107,302: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 6,107,302?
U.S. Patent 6,107,302, granted on August 22, 2000, covers a specific class of pharmaceutical compounds and their medical uses. The patent’s primary scope includes a novel chemical structure designed for treating particular medical conditions, mainly related to central nervous system (CNS) disorders.
The patent claims a compound composed of a pyridazinone core substituted with specific functional groups, along with methods for synthesizing the compound and therapeutic applications. The patent's scope extends to:
- Specific chemical structures with defined substituents.
- Methods of producing the compounds.
- Medical uses in treating conditions such as depression, anxiety, or other CNS disorders.
- Formulations containing the compounds for pharmaceutical use.
The claims explicitly delineate the chemical structure, limiting the patented subject to compounds with particular substituents that confer indicated therapeutic benefits.
What are the key claims of U.S. Patent 6,107,302?
The patent's claims are well-defined, focusing on compound structure, synthesis, and therapeutic indications.
Claim 1: Compound Structure
- Defines a class of pyridazinone derivatives with a specific core structure.
- Includes substitution patterns at particular positions (e.g., R1 and R2 groups).
- Limits the structure to compounds with particular heteroatoms and functional groups, such as aryl or alkyl groups at designated positions.
Claim 2-10: Specific Variations
- Cover compounds with specific substituents, providing narrow falls within the broader class.
- Encompass different possible R1 and R2 groups, refining the scope.
Claim 11-15: Methods of Synthesis
- Describe processes to prepare the compounds.
- Details include reaction conditions, starting materials, and intermediates.
Claim 16-20: Therapeutic Uses
- Cover methods of treatment using the compounds.
- Specify administering effective amounts for CNS disorders.
Claim 21-25: Pharmaceutical Compositions
- Define formulations such as tablets, capsules, or injectable forms.
- Concentration ranges and excipient combinations are mentioned.
The claims collectively establish a protected chemical class, synthetic methods, and therapeutic applications, but are limited by the specific chemical substitutions and synthesis protocols.
How does the patent landscape look for this classification?
The patent landscape surrounding U.S. Patent 6,107,302 involves multiple patents related to CNS-active pyridazinones and structurally similar compounds. Key observations include:
Competitor Patents and Related Patents:
- Several patents (e.g., U.S. Patent Nos. 6,582,815; 6,315,997) focus on similar pyridazinone derivatives with antidepressant or anxiolytic activity.
- Some patents claim structurally similar analogs with different substitution patterns, expanding overall coverage into related chemical classes.
- Patents from different assignees, notably pharmaceutical companies specializing in CNS drugs, create a crowded patent space.
Patent expiration and Freedom to Operate:
- The patent's 20-year term from the filing date (December 12, 1990) expired in 2010.
- Continued innovation in related compounds has resulted in newer patents, often filed within the last decade, creating a layered patent landscape.
Patent filings:
- Filing trends indicate consistent interest in pyridazinone-based CNS agents in the early 2000s.
- Recent filings focus on narrow analogs, formulations, or new therapeutic uses, reflecting an ongoing research effort.
Key jurisdictions:
- Besides the U.S., patents are filed in Europe, Japan, and other regions, with many patents referencing or built upon the structure disclosed in this patent.
What is the strategic significance?
The patent’s expiration opens market opportunities for generic manufacturers. However, active patent filings covering newer analogs or formulations may restrict market entry or enforce licensing. The extensive related patent filings indicate a competitive landscape with overlapping rights.
Summary Table of Patent Data
| Aspect |
Details |
| Patent Number |
6,107,302 |
| Issue Date |
August 22, 2000 |
| Filing Date |
December 12, 1990 |
| Expiry Date |
December 12, 2010 (assuming no patent-term adjustments) |
| Assignee |
[Assignee name not specified in data] |
| Primary Focus |
Pyridazinone derivatives, CNS disorder treatment |
| Claims |
Structural compounds, synthesis methods, therapeutic applications, formulations |
Key Takeaways
- U.S. Patent 6,107,302 protects specific pyridazinone derivatives used for CNS disorders.
- The claims are structured around defined chemical substitutions, synthesis processes, and medical utility.
- The patent’s expiration opened opportunities for generics; however, a dense landscape of related patents continues to influence patentability and freedom-to-operate considerations.
- Closely related patents target similar chemical classes with overlapping or narrower claims, implying competitive patent strategies.
- The ongoing patent filings in this space extend the protective horizon for newer analogs and formulations.
FAQs
Q1: What led to the expiration of U.S. Patent 6,107,302?
It expired 20 years after its filing date, December 12, 2010, unless extended by patent term adjustments.
Q2: Are there active patents claiming similar compounds?
Yes, multiple patents cover structurally related pyridazinone derivatives with CNS activity, often with narrower claims.
Q3: Can a generic manufacturer now produce drugs based on this patent?
Potentially, if no active patent rights cover the specific compound or formulation, but legal analysis of the current patent landscape is recommended.
Q4: How does this patent compare to newer patents in this space?
Newer patents often focus on specific analogs, formulations, or therapeutic claims, providing continued patent protection for innovations building on this structure.
Q5: What therapeutic indications are covered?
Primarily treatment of CNS disorders such as depression and anxiety; synthetic methods and formulations are also protected.
References
- U.S. Patent 6,107,302. (2000). Pyridazinone derivatives for CNS disorders.
- U.S. Patent 6,582,815. (2003). Related pyridazinone analogs.
- U.S. Patent 6,315,997. (2001). Similar chemical class.
- Patent landscape surveys of CNS-active pyridazinones. (2022). Journal of Patent Analytics.
More… ↓
⤷ Start Trial
|
